Fig. 1

Protein analyte concentrations of eotaxin-1 and eotaxin-2 in patients with asthma and COPD. Concentrations of eotaxin-1 and eotaxin-2 at baseline and after 52 weeks of treatment with benralizumab vs. placebo in the overall population of the asthma cohort (a and c). Concentrations of eotaxin-1 and eotaxin-2 at baseline and after 32 weeks of treatment with benralizumab vs. placebo in the overall population of the COPD cohort (b and d). Boxplots display the 25th–75th percentile values, with bars denoting median values. Boxes are labeled with the mean concentration per treatment arm. The dotted line denotes the analyte LLOQ. COPD, chronic obstructive pulmonary disease; FDR, false discovery rate; LLOQ, lower limit of quantification